Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Similares em SciELO
Compartilhar
Revista bio ciencias
versão On-line ISSN 2007-3380
Resumo
SANCHEZ-HERNANDEZ, L. et al. Different levels of expression of ALDH1A1 and DYRK1B in patients with glioblastoma multiforme and their overall survival. Revista bio ciencias [online]. 2020, vol.7, e762. Epub 18-Nov-2020. ISSN 2007-3380. https://doi.org/10.15741/revbio.07.e762.
Glioblastoma multiforme is the most malignant form of central nervous system astrocytoma. The overall survival median in patients with glioblastoma is 12 to 16 months after undergoing resection surgery, chemo radiotherapy and adjuvant treatment; However, it is still unclear which molecular factors are involved in the determination of overall survival. Recent reports pointed out a specific isoform of aldehyde dehydrogenase (ALDH1A1), a protein participating in cellular metabolic processes, as a potential biomarker in glioblastoma. In this study, the expression of ALDH1A1 in biopsies of glioblastoma from Mexican patients was identified and evaluated using immunohistochemical dyes, reverse transcription polymerase chain reaction (RT-PCR) and mass spectroscopy analyses. On the other hand, the presence of DYRK1B, a kinase involved in the regulation of tumor progression and in the regulation of the cell cycle was also analyzed using immunohistochemical detection and western blot. The purpose of this study was to investigate whether the histological expression, as well as the expression pattern of both proteins (ALDH1A1 and DIRK1B) presented a significant correlation with the overall survival in patients diagnosed with glioblastoma. Different expression patterns were found and both ALDH1A1 and DYRK1B showed similar expression patterns and an important correlation with the overall survival of patients. These findings allowed to consider the expression levels of ALDH1A1 and DYRK1B as possible prognostic factors in the diagnosis or possible biomarkers for survival time in patients with glioblastoma.
Palavras-chave : Glioblastoma; ALDH1A1; DYRK1B; survival time; immunohistochemistry; mass spectrometry.